Screening and expression analysis of lncRNAs in high-risk MDS
作者单位：Division of Clinical Biochemistry and Molecular Diagnostics in Center for Clinical Laboratory MedicineAffiliated Hospital to Guizhou Medical University
会议名称：《2019年中国肿瘤标志物学术大会暨第十三届肿瘤标志物青年科学家论坛》
会议日期：2019年
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
关 键 词：Myelodysplastic syndrome long-chain non-coding RNA lncRNA CDKN2-AS RUNX1 bioinformatics analysis
摘 要：Objection:Aimed to screen out the differentially expressed lncRNAs and verify its expression,exploring lncRNAs marker for diagnosis and therapeutics relevant to ***:Three cases bone marrow from patients with high-risk MDS and three healthy donors were collected respectively for lncRNA microarray;bioinformatics analysis was performed to predict the potential interactional targets of lncRNA;Peripheral blood of 20 patients with high-risk MDS and 20 healthy donors were employed for expression verification and co-expression analysis by SYBR-green ***:Microarray profiling indicated 150 differentially expressed lncRNAs in bone marrow of patients with high-risk MDS,of which 119 lncRNAs showed *** CDKN2-AS as a study target,which over-expressed in MDS with 3.27 folds of logFC compared to healthy *** analysis showed that RUNX1 was a potential target of mutual effect to CDKN2-AS;CDKN2-AS was highly expressed in 20 high-risk MDS patients,with a relative expression of 49.74±109.55,while low expressed in healthy donors with a relative expression of 0.56±2.35,significant difference was showed between the two groups,p0.01;while RUNX1 was low expressed in high-risk MDS patients,the relative expression level indicated significant difference in MDS and healthy donors,p ***:CDKN2-AS is a potential marker of MDS and its’ expression is associated with the prognosis of MDS.